How do you treat Lewy body dementia?

Treatment of Lewy Body Dementia

Start rivastigmine as first-line pharmacological therapy for Lewy body dementia, targeting both cognitive symptoms and neuropsychiatric features including hallucinations and delusions. 1, 2

Pharmacological Management

First-Line: Cholinesterase Inhibitors

Rivastigmine is the preferred cholinesterase inhibitor for Lewy body dementia based on the strongest evidence base, demonstrating statistically significant and clinically important improvements in global assessment measures. 1, 2

• Dosing: Titrate rivastigmine up to 6-12 mg daily, individualizing the dose based on tolerability. 2
• Expected benefits: Approximately 63% of patients show at least 30% improvement from baseline in neuropsychiatric symptoms, compared to only 30% on placebo. 2
• Specific symptom improvements: Patients experience significantly reduced apathy, anxiety, delusions, and hallucinations, with particular benefits in attentional tasks. 2
• Adverse effects: Common side effects include nausea, vomiting, and anorexia, but the drug is generally well-tolerated when titrated individually. 2
• Long-term use: Cognitive and neuropsychiatric improvements are maintained over 96 weeks, with scores not significantly worse than baseline even after nearly 2 years. 3

Alternative cholinesterase inhibitors (donepezil, galantamine) show beneficial effects in meta-analyses but have less robust evidence specifically for Lewy body dementia compared to rivastigmine. 4

Memantine

Memantine can be used for Lewy body dementia but should not be discontinued if already providing benefit for neuropsychiatric symptoms. 5

• Meta-analysis suggests memantine is well-tolerated but provides fewer benefits compared to cholinesterase inhibitors. 4
• The 2020 Canadian Consensus Conference supports memantine use specifically for DLB (along with AD, PDD, and VD). 5

Management of Refractory Psychosis

For cholinesterase inhibitor-resistant psychosis, consider pimavanserin as a safer alternative to traditional antipsychotics. 6

• Pimavanserin is well-tolerated in patients with DLB and may reduce distressful hallucinations, delusions, and paranoia when other medications fail. 6
• Avoid traditional antipsychotics (haloperidol, risperidone, olanzapine, quetiapine) due to severe neuroleptic sensitivity reactions common in Lewy body dementia. 2, 6

Hypersomnia Management

Armodafinil is recommended for hypersomnia secondary to Lewy body dementia. 1

Non-Pharmacological Interventions

Implement non-pharmacological approaches concurrently with medication, as these improve outcomes for both patients and caregivers. 1

• Group cognitive stimulation therapy for mild to moderate dementia. 1
• Exercise programs, though optimal duration and intensity remain undefined. 1
• Psychosocial and psychoeducational interventions for caregivers to reduce burden. 1
• Case management to improve care coordination and continuity. 1

Critical Prescribing Principles

When to Continue Treatment

Do not discontinue cholinesterase inhibitors in patients with clinically meaningful psychotic symptoms, agitation, or aggression until these symptoms stabilize, unless the medication clearly worsened symptoms. 5, 1

Continue cognitive enhancers indefinitely in patients who have achieved clinically meaningful reduction in neuropsychiatric symptoms, even if cognitive and functional decline progresses. 5, 1

When to Deprescribe

Gradual deprescribing is required if discontinuation becomes necessary. 5

• Reduce dose by 50% every 4 weeks until reaching the initial starting dose. 5
• After 4 weeks at starting dose, discontinue completely. 5
• Reinitiate treatment if clinically meaningful worsening occurs in cognition, function, neuropsychiatric symptoms, or global assessment. 5

Common Pitfalls

Avoid premature discontinuation when patients show cognitive decline but have stable neuropsychiatric symptoms—the behavioral benefits alone justify continuation. 5, 1

Do not use traditional antipsychotics as first-line for hallucinations or delusions, as Lewy body dementia patients have heightened sensitivity to neuroleptic side effects. 2, 6

Monitor for sleep disturbances, as these improve in the majority of patients treated with rivastigmine and represent an important quality-of-life outcome. 7